Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.

Events

Stock Quote

Change
Volume
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Announces Board of Directors Transition
Timothy Johnson to Retire from the Board; Ann Hanham, Ph.D. Remains Lead Independent Director TUCSON, Ariz. , Jan. 19, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that Timothy
Toggle Summary HTG Molecular Diagnostics Announces Certain Preliminary 2020 Unaudited Financial Results
Preliminary full year 2020 unaudited revenue of $8.5 million Cash, cash equivalents and short-term marketable securities of $28.7 million as of December 31, 2020 TUCSON, Ariz. , Jan. 05, 2021 (GLOBE NEWSWIRE) --   HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose
Toggle Summary HTG Expands Patent Portfolio with New Canadian Patent for its Nuclease Protection Methods for Detection of Nucleotide Variants
TUCSON, Ariz. , Dec. 30, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has received notification of the issuance of Canadian patent number 2877729 for “Nuclease
Toggle Summary HTG Announces First Collaborator in Early Access Program for its Prototype Whole Transcriptome Panel
TUCSON, Ariz. , Dec. 18, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has signed up the first collaborator in its recently announced Early Access Program for its
Toggle Summary HTG Announces an Early Access Program for its Prototype Whole Transcriptome Panel
TUCSON, Ariz. , Dec. 08, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has launched an Early Access Program for its whole transcriptome panel using the HTG EdgeSeq

Stock Chart

SEC Filings

Filing date Description

Report of unscheduled material events or corporate event

Securities offered to employees pursuant to employee benefit plans

Report of unscheduled material events or corporate event

Report of unscheduled material events or corporate event

Statement of changes in beneficial ownership of securities